-
公开(公告)号：US20190192490A1
公开(公告)日：2019-06-27
申请号：US16200303
申请日：2018-11-26
申请人： Lupin Limited
IPC分类号： A61K31/437 , A23L27/00 , A61K31/428 , A61K9/10
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
-
公开(公告)号：US11278502B2
公开(公告)日：2022-03-22
申请号：US16146237
申请日：2018-09-28
申请人： LUPIN LIMITED
IPC分类号： A61K9/50 , A61K47/38 , A61K31/165 , A61K9/20 , A61K47/32
摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
-
公开(公告)号：US10137114B2
公开(公告)日：2018-11-27
申请号：US14937730
申请日：2015-11-10
申请人： Lupin Limited
IPC分类号： A61K31/437 , A61K9/10 , A61K31/428 , A23L27/00
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
-
公开(公告)号：US20150209432A1
公开(公告)日：2015-07-30
申请号：US14417241
申请日：2013-07-22
申请人： LUPIN LIMITED
IPC分类号： A61K47/32 , A61K47/02 , A61K9/50 , A61K31/4439
CPC分类号： A61K47/32 , A61K9/1611 , A61K9/1635 , A61K9/1676 , A61K9/2004 , A61K9/2027 , A61K9/501 , A61K9/5026 , A61K9/5073 , A61K9/5078 , A61K31/4439 , A61K47/02
摘要： The present invention relates to pharmaceutical compositions of Proton Pump Inhibitor and process for preparation of such composition thereof. The invention relates to pharmaceutical compositions comprising Proton Pump Inhibitor, crospovidone, basic inorganic salt and one or more pharmaceutically acceptable excipients. The present invention provides stable pharmaceutical compositions of Dexlansoprazole which are bioequivalent to marketed dual delayed release pharmaceutical compositions of Dexlansoprazole.
摘要翻译： 本发明涉及质子泵抑制剂的药物组合物及其制备方法。 本发明涉及包含质子泵抑制剂，交聚维酮，碱性无机盐和一种或多种药学上可接受的赋形剂的药物组合物。 本发明提供了德兰索拉唑的稳定的药物组合物，其与德克唑索的市售双延迟释放药物组合物具有生物等效性。
-
公开(公告)号：US20190029968A1
公开(公告)日：2019-01-31
申请号：US16146237
申请日：2018-09-28
申请人： LUPIN LIMITED
IPC分类号： A61K9/50 , A61K47/38 , A61K47/32 , A61K9/20 , A61K31/165
摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
